CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Rivastigmine Patch +1 moredrug
Likely dose
Rivastigmine Patch 4.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00835159
NCT00835159Phase 4Completed
CompareCT.gov

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

NYU Langone Health·interventional·Posted Feb 3, 2009·Updated Feb 9, 2015

In Brief

A Phase 4 clinical trial evaluating Rivastigmine Patch and Placebo Patch for Delirium and Postoperative Cognitive Dysfunction. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether preoperative administration of Rivastigmine prevents the incidence of postoperative delirium in patients undergoing major surgery as well as postoperative cognitive dysfunction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDelirium, Postoperative Cognitive Dysfunction
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2009
Enrollment StartDec 1, 2008
Primary CompletionJul 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.4 years ago

Interventions

Rivastigmine Patchdrug

Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours

Placebo Patchother

A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.